Tandem Diabetes Care (NASDAQ:TNDM) Sets New 52-Week High Following Analyst Upgrade

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) reached a new 52-week high on Friday after Robert W. Baird raised their price target on the stock from $28.00 to $36.00. Robert W. Baird currently has a neutral rating on the stock. Tandem Diabetes Care traded as high as $47.00 and last traded at $46.06, with a volume of 1790113 shares changing hands. The stock had previously closed at $36.56.

TNDM has been the topic of several other reports. Citigroup raised their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Wells Fargo & Company upgraded Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $21.00 to $45.00 in a research report on Monday, April 29th. StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Friday, April 19th. Leerink Partnrs raised shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a report on Thursday, April 25th. Finally, SVB Leerink upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $34.00 to $45.00 in a research report on Thursday, April 25th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.45.

Institutional Investors Weigh In On Tandem Diabetes Care

A number of institutional investors have recently added to or reduced their stakes in the stock. MCF Advisors LLC increased its position in Tandem Diabetes Care by 79.3% during the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after buying an additional 445 shares in the last quarter. Van ECK Associates Corp grew its position in Tandem Diabetes Care by 8.6% during the 4th quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock worth $175,000 after purchasing an additional 467 shares during the period. Diversified Trust Co grew its position in Tandem Diabetes Care by 5.6% during the 4th quarter. Diversified Trust Co now owns 10,573 shares of the medical device company’s stock worth $313,000 after purchasing an additional 564 shares during the period. Raymond James & Associates raised its stake in shares of Tandem Diabetes Care by 1.9% during the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock valued at $836,000 after buying an additional 737 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Tandem Diabetes Care by 10.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock valued at $205,000 after buying an additional 908 shares during the period.

Tandem Diabetes Care Stock Up 22.3 %

The stock has a market cap of $2.89 billion, a PE ratio of -13.00 and a beta of 1.10. The business has a 50 day moving average price of $32.29 and a 200 day moving average price of $26.08. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. Equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.62 EPS for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.